Annual Digital Innovation Index by CNS Summit Highlights Industry Trends in Biopharma

CNS Summit Releases Annual Digital Innovation Index

BOSTON, Nov. 5, 2025 – The much-anticipated CNS Summit Digital Innovation Index has been unveiled during the CNS Summit annual meeting, held on November 4. This index is the result of a collaborative effort with IDEA Pharma, a branch of SAI Med Partners. The index aims to evaluate and rank biopharma companies based on their progress in digital innovation, focusing on three essential areas:

1. Technology Advancement
2. Clinical Trial Optimization
3. Collaborative Innovation

This year's edition places a strong emphasis on how organizations are incorporating AI-driven research into their processes. The results have shown that Roche continues to maintain its leading position from the previous year, reflecting a consistent dominance rather than isolated spikes in performance. This indicates a trend towards robust platform-based digital capabilities rather than sporadic successes.

Roche's innovative approach emphasizes the use of algorithms to create a supportive infrastructure for both patients and strategic collaborations. In 2025, it is accompanied by several other high-ranking companies, such as AstraZeneca, Sanofi, Pfizer, and Bayer. These firms are committed to fostering strategic partnerships, advancing digital innovation, and promoting global expansion.

Dr. Amir Kalali, Chairman and Chief Curator of CNS Summit, remarked, "CNS Summit has consistently acknowledged and stimulated digital and research development innovation. We are excited to continue this independent effort to benchmark the performance of life science firms."

Mike Rea, CEO of IDEA Pharma, stated, "Now a decade since its inaugural launch, the CNS Summit Digital Innovation Index continues to reveal pivotal trends and successful applications of digital innovation within the industry. This past year marks a significant transition in biopharma—moving from the mere promise of progress to tangible change that is reshaping how the sector delivers outcomes for patients. Digitalization is no longer an additional aspect or a temporary pilot; it has become fully integrated into the core of businesses, from discovery to delivery. This year specifically, we are witnessing unprecedented involvement of generative AI in discovery processes, streamlined AI workflows that minimize inefficiencies in clinical timelines, medications combined with software for enhanced reach, and widespread remote monitoring integration turning decentralized trials from an optional feature into the standard operating procedure. The industry has awakened to the possibilities that lie ahead, and we eagerly anticipate the long-term benefits that true digital innovation integration will yield and its impact on patient care."

For detailed information about the comprehensive 2025 rankings, visit cnssummit.org/innovation-index.

For any inquiries, please contact the CNS Summit Secretariat at 858-324-1823 or via email at CNS Summit Secretariat. Additionally, you can reach out to Jacqueline Poot at IDEA Pharma via email at Jacqueline Poot.